NCI Drug Discovery Program Pays Off

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Division of Cancer Treatment, said that over the past decade, NCI's drug discovery and development programs have produced seven new drugs currently being used to treat cancer and AIDS. The program cost about $1.4 billion: $200 million for every New Drug Application filed.

ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Divisionof Cancer Treatment, said that over the past decade, NCI's drugdiscovery and development programs have produced seven new drugscurrently being used to treat cancer and AIDS. The program costabout $1.4 billion: $200 million for every New Drug Applicationfiled.

Dr. Chabner made the report to the National Cancer Advisory Board'sAd Hoc Working Group on NCI Intramural Programs. He added thatduring the decade, increases in AIDS research funding has hada significant effect on the intramural research program. "Intramuralscientists have shifted the focus of their research to followthe money," he said.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content